A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

Novotná, Alena; Mareš, Jan; Ratcliffe, S.; Nováková, Iveta; Vachová, Marta; Zapletalová, Olga; Gasperini, Claudio; Pozzilli, Carlo; Ausili Cefaro, Luca; Comi, Giancarlo; Rossi, Paolo; Ambler, Zdeněk; Stelmasiak, Z; Erdmann, Alf-Peter; Montalbán, Xavier; Klimek, A; Davies, Paul; Sativex Spasticity Study Group, the

doi:10.1111/j.1468-1331.2010.03328.x

Public

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

Published in European Journal of Neurology • Mar 1, 2011

Authors:

Alena Novotná

Jan Mareš

S. Ratcliffe

Abstract

BACKGROUND: Spasticity is a disabling complication of multiple sclerosis, affecting many patients with the condition. We report the first Phase 3 placebo-controlled study of an oral antispasticity agent to use an enriched study design. METHODS: A 19-week follow-up, multicentre, double-blind, randomi...

Subject

Medicine

Placebo

Spasticity

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!